Melanoma—Part 1: epidemiology, risk factors, and preventionBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a2249 (Published 20 November 2008) Cite this as: BMJ 2008;337:a2249
- Veronique Bataille, consultant dermatologist1, senior research fellow 2,
- Esther de Vries, senior cancer epidemiologist3, epidemiology consultant 43
- 1West Hertfordshire Hospitals NHS Trust, Hemel Hempstead HP2 4AD
- 2Twin Research and Genetic Epidemiology Unit, King’s College London SE1 7EH
- 3Department of Public Health, Erasmus MC University, Medical Center, Rotterdam, Netherlands
- 4Department of Dermatology, Erasmus MC University Medical Center, Rotterdam
- Correspondence to: V Bataille
The incidence of melanoma is rising, but most of the rise is caused by very thin melanomas
The most powerful risk factor for melanoma is the number of naevi
There are two phenotypic pathways to melanoma: via naevi or via sun damage
Melanoma mortality has been relatively stable over the past 30 years
A reduction in people’s exposure to sun has not led to a significant reduction in the incidence of melanoma, and sun avoidance may be detrimental; secondary prevention with early detection of melanoma saves lives
The incidence of melanoma has risen over the past 30 years in most white populations.1 2 However, in some parts of the world incidence rates are stable or falling. Although large scale primary prevention programmes such as public health education campaigns aimed at reducing exposure to sun may lead to reduced incidence, such programmes have not yet been proved effective. However, melanoma is highly amenable to secondary prevention through early detection. Being able to recognise a melanoma early is an important skill for primary healthcare practitioners. In this first article of a two part series on melanoma, we examine the evidence on the genetic epidemiology of melanoma and outline the complex interactions between incidence, mortality, and survival trends; we also discuss the evidence for prevention.
How common is melanoma?
Although melanoma remains a relatively rare tumour, many European countries show an annual increase in incidence above 2%; in some northern European countries, however, no significant increase has been observed.1 Between 1992 and 2005, the annual increase in incidence rates of melanoma in the United States was 2.3% for all races and 2.8% in white populations.3 Queensland in Australia had an increase in incidence of 1.4% for males and 0.7% for females during 1982 to 2001.4 Most recent incidence data show that in some parts of the US, Australia, and the United Kingdom, incidence of melanoma has reached a plateau and even started to decrease.3 5
Should we be concerned by a rising incidence of melanoma?
Examining incidence, mortality, and survival trends for melanoma together can produce a clear picture of the scale of the problem. Incidence has been inflated by early lesions that have little potential to spread and have a low impact on mortality.6 In countries with health education campaigns related to skin cancer, much of the rise in incidence can be attributed to very thin melanoma lesions or melanomas in situ.
In Australia, for example, an epidemiological study that reviewed cancer registries showed that the rate of increase of melanoma in situ has been about 9% a year compared with only 2.8% for invasive melanomas.2 Over the same period the incidence of thin melanomas has increased faster than that of thick tumours, which have not become much more common.2 Although thin lesions are diagnosed on average five to 10 years earlier than thick ones, this does not necessarily suggest that they are detected shortly before they become invasive.2 Earlier diagnosis is more likely to reflect a trend in younger patients attending screening.
In contrast with the data on rising incidence, mortality curves for melanoma have been fairly flat over the past 30 years in most white populations and have even begun to fall in the US, Australia, Scandinavia, and the UK.1 7 Early melanomas (often in situ tumours) are increasingly being excised, and comparisons of incidence and mortality data suggest that many borderline lesions may never progress if left alone.2
Who gets melanoma?
The mean age of presentation with melanoma is about 55 years, but this may vary according to thickness and histological subtype.3 Superficial spreading melanomas, usually thinner tumours, are seen in younger individuals, whereas nodular melanoma and lentigo maligna melanoma tend to affect older individuals.
Men and women are generally equally likely to be diagnosed with melanoma, but in some countries a slight female preponderance is seen.1 The most common site for women is the legs and for men the trunk.8 9 That the difference is attributable to different patterns of sun exposure in men and women is unlikely because a difference in site according to sex is seen in countries with differing sun exposure and clothing habits. For example, the site distribution of melanoma according to sex is similar in Australia, the UK, and Israel despite different skin exposure habits between the three countries.10 Site differences according to sex are likely to reflect genetic differences as naevi are also differently distributed between boys and girls from an early age.11
What are the risk factors for melanoma?
Exposure to sun
Although sun exposure has long been suspected to be a risk factor for melanoma, the relation between sun exposure and melanoma is complex. The evidence that sun exposure may be associated with melanoma is apparent when comparing incidence in Australia and sunny parts of the US with Europe.3 The incidence of melanoma is three to four times higher in Queensland, Australia, than in the UK.2 However, a significant association between sun exposure behaviour and melanoma is less easy to show in a case-control setting.12 13 A meta-analysis of melanoma case-control studies found low relative risks associated with various measures of exposure to ultraviolet radiation, and the relation with sunshine was not dose dependent.14 Sharp, short bursts of acute exposure in childhood, and severe sunburn, were most strongly associated with melanoma. However, cumulative occupational exposure seemed to be protective in some white populations. Odds ratios associated with sun exposure are often no longer significant after adjustment for skin type, which supports a hypothesis that host response to ultraviolet radiation is more important than dose of sun exposure.
Use of sun beds
Melanoma is controversially associated with use of sunbeds. Some epidemiological studies have not found sunbed use to be a significant risk, whereas others have found small increased risks.13 15 16 17
Sunbed use seems to be most detrimental before the age of 20, and current recommendations are that sunbeds should be avoided, especially in relating to premature skin ageing.17 Individuals with red hair and freckles, or multiple atypical naevi, with or without a family history of melanoma, should avoid sunbeds since their risks of developing both melanoma and non-melanoma skin cancer are already significantly increased.18
Having fair skin with a poor ability to tan, or a freckled complexion with or without red hair, doubles a person’s risk of melanoma.18 Polymorphisms in the melanocortin 1 receptor (MC1R) gene have been linked to fair skin and red hair and have been associated with an increased risk of melanoma.19 20
Melanomas present rarely in non-white people, in whom the incidence is 10 to 20 times lower than in white people.3 Body site and histological subtypes differ between white and non-white people. The latter more frequently present with lentiginous and nodular melanoma on the palms and soles and rarely on other parts of the body.3 21
Naevi are the most powerful predictor of risk of melanoma. A meta-analysis of observational studies found that an individual who has more than 100 common naevi or more than two atypical naevi has a fivefold to 20-fold increased risk of melanoma.22 Unlike melanoma, atypical naevi (fig 1⇓) are usually symmetrical and do not have a sharp edge with geographical border; asymmetry and sharp edged borders are clear signs of malignant transformation (fig 2⇓).23 Furthermore, naevi remain static whereas melanoma change in size, shape, or colour over weeks or months.
In younger individuals atypical naevi on the trunk and limbs are more predictive of superficial melanoma than of nodular melanoma or lentigo maligna melanoma, which affect older individuals with more sun damage and fewer naevi.24 w1 The presence of multiple common naevi and atypical naevi denotes the phenotype for atypical mole syndrome, which may indicate a genetic susceptibility to melanoma (boxes 1 and 2). This phenotype is found in about 2% of a healthy population in the UK.w2
Box 1 What to look for when a naevus changes
Change in size
Naevi may change in size over years, but any change over weeks or months is suspicious
Change in colour
Melanomas often show irregular pigment in a lesion, with shades of black, brown, grey, and pink. In nodular melanoma the lesion is often black throughout. Rarely a melanoma can present as a non-pigmented red nodule (amelanocytic melanoma); this is more likely on hands and feet
Change in outline
Melanomas often show a geographical outline with a sharp cut-off from normal skin
Itching may be a late sign and is often unreliable as many benign naevi intermittently itch
Bleeding is also a late sign and is often present in advanced melanoma
Box 2 Phenotype for atypical mole syndrome
What are the features of the phenotype?
More than 100 common naevi (≤2 mm in diameter)
More than two atypical naevi (≥5 mm in diameter)
Naevi on unusual sites such as breasts in females, buttocks, scalp, ears, dorsum of feet
When the phenotype is present
If there is also a family history of melanoma or multiple cancers, referral to a dermatologist is recommended
Removal of atypical naevi just to confirm histological dysplasia is not helpful. Lesions should be removed only if early melanoma is suspected and only by an experienced clinician
Two twin studies suggest that naevi are under considerable genetic control, with a 60% concordance in numbers of naevi in identical twins.w3 w4 A cross sectional twin study of over 2000 individual twins showed that naevi undergo senescence with age, with a decrease in numbers from the age of 30 to 40 years, but that in patients with the atypical mole syndrome the number of naevi can remain high after middle age.w3 In patients with the syndrome, naevi are also often found on unusual sites, such as scalp, buttocks, feet, hands, and irises.w5
Solar keratoses carry a relative risk for melanoma of 2 to 4.w6 w7 The presence of naevi and solar keratoses is often mutually exclusive, suggesting different pathways to melanoma—via an excess of naevi in younger individuals or via chronic sun damage and cumulative sun exposure in older subjects.24 w6 w7
Family history of melanoma and genetic factors
Five to ten per cent of individuals with melanoma have a family history of melanoma.w5 In families with melanoma, affected individuals often have the atypical mole syndrome phenotype (fig 3⇓). About a quarter of all families with melanoma have been linked to mutations in the tumour suppressor gene CDKN2A/p16 on chromosome 9p21, which affects the germline and is therefore transmitted through generations.w8 Mutation screening outside the research setting is not recommended as the prevalence of germline CDKN2A mutations is very low and does not alter management.23 In some families with melanoma, susceptibility to some other cancers—such as pancreas, brain, and breast cancer—is increased, so taking a thorough family history of cancers in patients with melanoma is important.w9
Mortality studies have shown that women have thinner tumours and survive melanoma better than men even after adjustment for Breslow thickness, ulceration, and body site, which suggests that there may be X linked variable gene expression or hormonal factors affecting melanoma survival.9 w10 Anecdote reports melanoma behaving aggressively during pregnancy and metastases manifesting themselves during pregnancy. However, a meta-analysis that examined data on over 5000 female participants showed that risk of melanoma was not affected by pregnancy, oral contraception, or hormone replacement.w11
Can melanoma be prevented?
Primary prevention—benefits and harms
Health education campaigns aimed at reducing people’s exposure to sun began in Australia in the 1980s and were soon adopted elsewhere in the world. There is, as yet, no direct evidence that reducing sun exposure has had an effect on melanoma incidence. Some commentators have suggested that the slowing down and even downturn in incidence in melanoma in some parts of the world may be due to the health education programmes, but the downturn has been seen in parts of the world where levels of sun exposure and public health campaigns vary.4 Furthermore, the lag time between change in behaviour and the recent downturns in incidence may have been too short for health education to be the sole explanation.
A recent BMJ editorial raised a concern that drastic reduction of sun exposure in temperate climates may have an impact on health because of low vitamin D levels.w12 Vitamin D is important for bone metabolism but has also been shown to have protective effects against inflammation, cancer, psychiatric diseases, and autoimmune disease. Avoiding sunburn and excessive sun exposure without protection seems to be the most important message in skin cancer prevention without advocating keeping away from the sun altogether.w13 More research is needed in this field to understand not only the relation between melanoma and sun exposure but also the potential detrimental effects of vitamin D deficiency after sun avoidance.
Secondary prevention—early identification and treatment
Melanoma is amenable to secondary prevention as tumours are highly visible with a good prognosis if detected early. Secondary prevention is a more efficient way to reduce mortality from melanoma than primary prevention as the latter has not yet been proved to reduce incidence or mortality significantly. However, for secondary prevention to be successful, educating the public and health professionals to recognise melanoma early is crucial.
Is there any benefit in screening?
Screening strategies have not yet been formally assessed as the design of such trials is difficult. Individuals with multiple atypical naevi, a family history of melanoma, and/or multiple cancers should be referred to a dermatologist for screening as their risk of melanoma is significantly increased.23 However, melanoma is an uncommon cancer and population screening may not yield a substantial number of cases. Public health campaigns depicting melanoma as a serious killer are no longer accurate as more than 80% of patients with melanoma now survive their disease, with most melanomas being treated with relatively minor surgery alone.1 7 Concern has been expressed that aggressive public health campaigns lead to anxiety related increases in the excision of benign lesions and melanoma in situ.w14 In Australia, where melanoma screening is most active, a sharp rise in melanoma in situ and very thin melanomas has been observed over the past 10 years, thus inflating incidence figures.2 There is certainly a need to educate the public on what to look for when a mole changes, while avoiding generating anxiety and the subsequent removal of too many benign lesions.
Questions for future research
Why does body site and survival differ so much by sex in melanoma?
Will the discovery of low penetrance susceptibility genes for melanoma help us in targeting populations at risk?
Is a reduction in people’s exposure to sun reducing the incidence of melanoma?
Are recent trends in melanoma explained by increased surveillance and ascertainment of very early non-invasive tumours and not by a genuine increase in the incidence?
Additional educational resources
Resources for patients
GenoMEL (www.genomel.org/english/patientInformation.htm)—GenoMEL (Melanoma Genetics Consortium) has available a booklet, Melanoma: Dealing with the Diagnosis
Royal College of Physicians. Prevention, diagnosis, referral and management of melanoma of the skin. Concise guideline No 7. www.rcplondon.ac.uk/pubs/brochure.aspx?e=216
British Association of Dermatologists (www.bad.org.uk/public/leaflets/melanoma.asp)—Leaflet and contacts for support
Cancer Research UK (www.cancerhelp.org.uk/help/default.asp?page=2788)—Advice on melanoma
Resources for health professionals
GenoMEL (www.genomel.org/english/physicianInformation.htm)—GenoMEL (Melanoma Genetics Consortium) gives information and references on melanoma
National Cancer Institute. Surveillance epidemiology and end results. (http://seer.cancer.gov/faststats/selections.php?run&output=2&data=1&statistic=2&year=200802&race=2&sex=1&age=1&series=cancer&cancer=53)
Cancer Research UK (http://info.cancerresearchuk.org/cancerstats/types/skin/incidence/)—Gives statistics on skin cancer
Information Services Division Scotland (www.isdscotland.org/isd/1048.html#Malignant%20melanoma%20of%20the%20skin)—Data, reports, and factsheets.
Melanoma Molecular Map Project (www.mmmp.org)—Six interconnected databanks for the interactive collection, update, and consultation of the translational and clinical information on melanoma biology and treatment
National Institute for Health and Clinical Excellence. Skin tumours including melanoma. (Cancer service guidance.) 2006. www.nice.org.uk/Guidance/CSGSTIM [Note to A - I’ve used shorter URL]
Department of Health. Guidelines for the appointment of general practitioners with special interests in the delivery of clinical services: dermatology. 2003. www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4008233
Cite this as: BMJ 2008;337:a2249
Contributors: VB and EdeV both contributed to the writing and editing of the article and approved the final version. The guarantor is VB.
Competing interests: None declared.
Provenance and peer review: Commissioned; externally peer reviewed.
Patient consent obtained.